Deferred cytoreductive nephrectomy is associated with better survival compared with upfront surgery, including among fit patients receiving immunotherapy. Deferred cytoreductive nephrectomy (CN ...

MRCC delivered a total annualized dividend yield and our trading price of 11.4% using our February 28, 2025 closing share price. We are proud of our longstanding track record of delivering ...

Shares of MRCC stock opened at $8.81 on Monday. The company has a quick ratio of 4.37, a current ratio of 4.37 and a debt-to-equity ratio of 1.49. Monroe Capital has a twelve month low of $6.97 ...